The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical StudiesChiranjib Chakraborty, Sang‐Soo Lee, Ashish Ranjan Sharma et al.|Frontiers in Pharmacology|2021Cited by 167
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 VariantsChiranjib Chakraborty, Sang‐Soo Lee, Ashish Ranjan Sharma et al.|mBio|2021Cited by 89
COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patientsChiranjib Chakraborty, Govindasamy Agoramoorthy, Ashish Ranjan Sharma et al.|Journal of Medical Virology|2020Cited by 78
The current second wave and COVID-19 vaccination status in IndiaChiranjib Chakraborty, Sang‐Soo Lee, Ashish Ranjan Sharma et al.|Brain Behavior and Immunity|2021Cited by 67
Consider TLR5 for new therapeutic development against COVID‐19Chiranjib Chakraborty, Govindasamy Agoramoorthy, Ashish Ranjan Sharma et al.|Journal of Medical Virology|2020Cited by 60